Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torben Bjerregaard Larsen

Showing results (1-10 of 185) with videos related to

Pageof 19
Sort By:
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 25, 2014
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patientsTorben Bjerregaard Larsen
Ugeskrift for Laeger|December 1, 2015
[Unprovoked venous thromboembolism: Should we be looking for cancer?]Torben Bjerregaard Larsen
Cardiology|December 10, 2025
From Provocation to Precision: The Evolution of Flow-Based Thrombosis ModelsTorben Bjerregaard Larsen
The Lancet. Haematology|January 15, 2016
Risk of venous thromboembolism in patients with heart failureTorben Bjerregaard Larsen
Lancet (London, England)|August 13, 2016
Stroke and mortality after atrial fibrillation-a global struggleTorben Bjerregaard Larsen, Peter Brønnum Nielsen
Thrombosis Research|April 20, 2010
Severe arterial thrombosis in a family with type III protein S deficiency caused by a frameshift mutation in the PROS1 geneTorben Bjerregaard Larsen, Klaus Brusgaard, Mads Nybo
Lancet (London, England)|December 10, 2013
Warfarin or novel oral anticoagulants for atrial fibrillation?Torben Bjerregaard Larsen, Gregory Y H Lip
Thrombosis and Haemostasis|July 12, 2012
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillationFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen
Circulation|December 21, 2018
Response by Overvad et al to Letter Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA<sub>2</sub>DS<sub>2</sub>-VA Score Rather Than CHA<sub>2</sub>DS<sub>2</sub>-VASc?"Thure Filskov Overvad, Torben Bjerregaard Larsen, Peter Brønnum Nielsen
Journal of General Internal Medicine|May 6, 2015
Comparison of Atrial Fibrillation GuidelinesThure Filskov Overvad, Peter Brønnum Nielsen, Torben Bjerregaard Larsen
Pageof 19

Showing results (1-10 of 185) with videos related to

Sort By:
Pageof 19
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 25, 2014
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patientsTorben Bjerregaard Larsen
Ugeskrift for Laeger|December 1, 2015
[Unprovoked venous thromboembolism: Should we be looking for cancer?]Torben Bjerregaard Larsen
Cardiology|December 10, 2025
From Provocation to Precision: The Evolution of Flow-Based Thrombosis ModelsTorben Bjerregaard Larsen
The Lancet. Haematology|January 15, 2016
Risk of venous thromboembolism in patients with heart failureTorben Bjerregaard Larsen
Lancet (London, England)|August 13, 2016
Stroke and mortality after atrial fibrillation-a global struggleTorben Bjerregaard Larsen, Peter Brønnum Nielsen
Thrombosis Research|April 20, 2010
Severe arterial thrombosis in a family with type III protein S deficiency caused by a frameshift mutation in the PROS1 geneTorben Bjerregaard Larsen, Klaus Brusgaard, Mads Nybo
Lancet (London, England)|December 10, 2013
Warfarin or novel oral anticoagulants for atrial fibrillation?Torben Bjerregaard Larsen, Gregory Y H Lip
Thrombosis and Haemostasis|July 12, 2012
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillationFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen
Circulation|December 21, 2018
Response by Overvad et al to Letter Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA<sub>2</sub>DS<sub>2</sub>-VA Score Rather Than CHA<sub>2</sub>DS<sub>2</sub>-VASc?"Thure Filskov Overvad, Torben Bjerregaard Larsen, Peter Brønnum Nielsen
Journal of General Internal Medicine|May 6, 2015
Comparison of Atrial Fibrillation GuidelinesThure Filskov Overvad, Peter Brønnum Nielsen, Torben Bjerregaard Larsen
Pageof 19